PureTech Founded Entity Vedanta Biosciences Announces $25 Million Investment from Pfizer Inc. Michael Vincent, M.D., Ph.D., Chief Scientific Officer, Inflammation & Immunology Research Unit at Pfizer, to join Vedanta s Scientific Advisory Board
PureTech Health plc (LSE: PRTC, NASDAQ: PRTC) ( PureTech or the Company ), a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases , is pleased to note that its Founded Entity, Vedanta Biosciences, today announced that Pfizer Inc. (NYSE: PFE) has made a $25 million investment in Vedanta, as part of the Pfizer Breakthrough Growth Initiative . Vedanta intends to use the proceeds to fund a Phase 2 study of VE202 in inflammatory bowel disease (IBD), which it plans to initiate in 2021.
An MGH pilot study evaluating scalp skin disruption using Follica’s proprietary Hair Follicle Neogenesis stimulation product was published in International Journal of Women’s Dermatology, demonstrating the treatment promoted hair growth in female pattern hair loss. The study endpoints included photographs, patient-reported improvement and physician-documented Sinclair score.
The pilot study, led by Maryanne M. Senna, M.D., an assistant professor of dermatology at Harvard Medical School, enrolled 11 women with mild to moderate FPHL who had been on stable existing treatments for six or more months. Patients underwent six treatments with the Follica proprietary Hair Follicle Neogenesis (HFN) device and application of a topical on-market drug on non-treatment days. The scalp treatments with the HFN device, which last just a few minutes, stimulate stem cells and enable the growth of new hair follicles. A topical drug is then applied to enhance efficacy by thickening new hair follicle
Study will further evaluate safety and tolerability of LYT-100 and explore clinical efficacy endpoints in patients with breast-cancer related, upper limb secondary lymphedema Previously announced results from multiple ascending dose and food effect study in healthy volunteers demonstrated favorable tolerability and pharmacokinetic proof-of-concept for LYT-100 A separate Phase 2 study evaluating LYT-100 in Long COVID respiratory complications and related sequelae was recently initiated
PureTech Health plc (LSE: PRTC, Nasdaq: PRTC) ( PureTech or the Company ), a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, today announced the initiation of a Phase 2a proof-of-concept study of LYT-100 (deupirfenidone) in patients with breast cancer-related, upper limb secondary lymphedema